Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease

Lamya H. Al-Wahaibi a,*, Ahmed Mostafa b, Yaser A. Mostafa c, Ola F. Abou-Ghadir c, Ahmed H. Abdelazeem d, e, Ahmed M. Gouda d, Omnia Kutkat h, Noura M. Abo Shama b, Mahmoud Shehata b, Hesham A.M. Gomaa f, Mostafa H. Abdelrahman g, Fatma A. M. Mohamed h, i, Xuyuan Gu j, Mohamed A. Ali b, Laurent Trembleau k, Bahaa G.M. Youssif c, * a

a Department of Chemistry, College of Sciences, Princess Nourah Bint Abdulrahman University, Saudi Arabia
b Chemistry Department, Faculty of Science, Alexandria University, Alexandria 21321, Egypt
c Pharmacology Department, College of Pharmacy, Jouf University, Sakaka, Aljouf 72341, Saudi Arabia
d Department of Medicinal Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt
e Department of Pharmaceutical Sciences, College of Pharmacy, Assiut University, Assiut 71526, Egypt
f Department of Pharmaceutical Sciences, College of Pharmacy, Riyadh Elm University, Riyadh 11681, Saudi Arabia
g Pharmacology Department, College of Pharmacy, Jeddah University, Sakaka, Aljouf 72341, Saudi Arabia
h Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt
i Chemistry Department, Faculty of Science, Alexandria University, Alexandria 21321, Egypt
j Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
k Department of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt

ABSTRACT

We have discovered a family of synthetic oxazole-based macrocycles to be active against SARS-CoV-2. The synthesis, pharmacological properties, and docking studies of the compounds are reported in this study. The structure of the new macrocycles was confirmed by NMR spectroscopy and mass spectrometry. Compounds 13, 14, and 15a-c were evaluated for their anti-SARS-CoV-2 activity on SARS-COV-2 (NRC-03-nhCoV) virus in Vero-E6 cells. Isopropyl triester 13 and triacid 14 demonstrated superior inhibitory activities against SARS-CoV-2 compared to carboxamides 15a-c. MTB cytotoxicity assays showed that the OC50 (50% cytotoxicity concentration) of 13, 14, and 15a-c ranged from 159.1 to 741.8 μM and their safety indices ranged from 2.50 to 39.1. Study of the viral inhibition via different mechanisms of action (viral adsorption, replication, or virucidal property) showed that 14 had mild virucidal (60%) and inhibitory effects on virus adsorption (66%) at 20 μM concentrations. Compound 13 displayed several inhibitory effects at three levels, but the potency of its action is primarily virucidal. The inhibitory activity of compounds 13, 14, and 15a-c against the enzyme SARS-CoV-2 Mpro was evaluated. Isopropyl triester 13 had a significant inhibition activity against SARS-CoV-2 Mpro with an IC50 of 2.58 μM. Large substituents on the macrocyclic template significantly reduced the inhibitory effects of the compounds. Study of the docking of the compounds in the SARS-CoV-2-Mpro active site showed that the most potent macrocycles 13 and 14 exhibited the best fit and highest affinity for the active site binding pocket. Taken together, the present study shows that the new macrocyclic compounds constitute a new family of SARS-CoV-2-Mpro inhibitors that are worth being further optimized and developed.

1. Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) virus was first detected in China’s Wuhan province at the end of 2019 and has greatly affected human societies due to the global pandemic. The new virus has now infected over 120 million people around the world and resulted in over 2.6 million deaths [1–5]. SARS-CoV-2, like SARS-CoV and MERS-CoV, belongs to the genus Beta coronavirus and is responsible for the infection of the lower respiratory tract in particular, resulting in the disease COVID-19 [1,6]. SARS-CoV-2 is a 30,000-base
pair single stranded RNA virus, which possesses an envelope containing spike (S) proteins on its surface which binds with high affinity to the human angiotensin-converting enzyme 2 (ACE2) embedded in the membrane of cells found in the lungs, heart, kidneys, intestines, and arteries. This results in the infection of these cells by the virus [1,7]. The incubation time can vary from 2 days up to 24 days and is asymptomatic in many cases, which facilitated the virus transmission [6]. Several efficient and safe vaccines have rapidly been developed by several pharmaceutical companies [7]. The production of sufficient doses for the vaccination of the world population has proved challenging with the concomitant threat of the emergence of vaccine-resistant variants of the virus.

Very few known drugs have proved effective in reducing the gravity of the disease in severely affect patients with COVID-19 [2,6]. COVID-19-related research has been able to elucidate many druggable SARS-CoV-2 targets, including the spike (S) protein, the 3-chymotrypsin-like protease/main protease (3CL\textsuperscript{pro}/M\textsuperscript{pro}), the papain-like protease (PL\textsuperscript{pro}), and the RNA-dependent polymerase [3,7]. Of these, viral proteases PL\textsuperscript{pro} and M\textsuperscript{pro} constitute the most promising targets for the development of effective drugs against SARS-CoV-2. Viral proteases in coronaviruses are responsible for the development of non-structural proteins (nsps) by processing viral RNA translated polyproteins [3–4,7]. Thus, M\textsuperscript{pro} and PL\textsuperscript{pro} have acknowledged a great deal of publicity for their significant role in the enzymatic operation leading to their post-translational treatment of replicate polyproteins that are essential to the life cycle of the corona virus [8–16]. In the last year, several peptide-like derivatives were introduced as COVID-19 M\textsuperscript{pro} inhibitors I–IX as shown in Fig. 1 [17–21]. Virtual screening and docking studies have played a pivotal role in the discovery of these kinds of inhibitors.

On the other hand, more than 40 cyclic peptides are used clinically in treatment of different diseases [22]. These peptides came from natural and synthetic origin. Takagi \textit{et al}. have reported a series of cyclic peptide as NS2B-NS3 protease inhibitor [23]. The design of these peptides was done to mimic the substrate of NS2B-NS3 protease. Among this series, the cyclic peptide X (Fig. 2) exhibited inhibitory activity of NS2B-NS3 protease of dengue virus at IC\textsubscript{50} of 0.95 \(\mu\)M. Aspergill peptide D XI is a natural product isolated from \textit{Aspergillus} sp and exhibited inhibitory activity against herpes simplex virus type 1 at IC\textsubscript{50} value of 9.5 \(\mu\)M [24].

The eight-residue cyclic D,L-\(\alpha\)-peptide XII exhibited antiviral activity against adenovirus infection without an apparent adverse effect on cell viability [25]. The plausible mechanism of action of this compound could be mediated by targeting endosomal compartments in pH-dependent viral infections. Liang \textit{et al}. have reported a series of cyclic peptide XIII with significant antifungal and obvious antiviral activity against herpes simplex virus [26]. Among these derivatives, Simplicilliumtide J XIV exhibited significant antiviral activities against herpes simplex virus type 1 (IC\textsubscript{50} = 14.0 \(\mu\)M) [26].

The cyclic peptide ICU-1 (XI) was designed as potential anti-COVID-19 activity [27]. The design was performed using SARS coronavirus (SARS-CoV) main protease bound to a peptide substrate, which was modified to give a cyclic peptide inhibitor VI. A molecular docking study was used to illustrate the binding interactions of the designed peptide with main protease of both SARS-CoV and SARS-CoV-2.

Macrocyclic peptides are notoriously promising privilege structures in drug discovery due to their improved selectivity and stability against proteolytic enzymes in addition to their higher membrane permeability compared to their linear counterparts [28,29].

Motivated by the aforementioned data and over the course of the screening of in-house collections of molecules we discovered that a family of oxazole-based macrocycles, previously developed for other applications [30–32] possessed significant activity against SARS-CoV M\textsuperscript{pro}. The large macrocyclic structures were made following the work of Rebek \textit{et al} who developed this type of nature-inspired molecules for applications in supramolecular chemistry [30] and tackle the inhibition

![Peptide-like inhibitors of COVID-19 M\textsuperscript{pro}](Fig. 1)
Fig. 2. Cyclic peptides with antiviral activity.

Fig. 3. Structures of marine natural product dolastatin E, Rebek platform, galanin receptor agonist Galmic, and the bioactive oxazole-based macrocycles studied herein.
of protein–protein interactions [31,32] (Fig. 3).

We report herein the inhibitory activity of the new macrocyclic compounds 13, 14, and 15a-c (Fig. 3) against the SARS-COV-2 main protease, their pharmacological properties in infected Very-E6 cells, and results of docking studies in the SARS-COV-2 main protease active site.

2. Results and discussion

2.1. Chemistry

The synthesis of the macrocyclic compounds is largely inspired from the synthesis of Rebek triacid platform and Galmic [30–32]. However, we prepared the required oxazole building blocks having the opposite absolute configuration to that required for the synthesis of Galmic, leading to a slightly simplified synthesis of the macrocycles.

Enantiomerically pure amino acid 6 was prepared in five steps from commercially available amino diester 1 (Scheme 1). Boc-protection of this compound followed by α-methylation, and kinetic resolution using pig liver esterase gave enantiomerically pure Boc-protected amino acid 4. This compound was then esterified as an isopropyl ester and the methyl ester was hydrolyzed to afford the required compound 6 in good overall yield.

Oxazole isopropyl amino ester building block 12 was then obtained from compound 6 by performing a sequence of reactions similar to those described for the synthesis of the Rebek platform (Scheme 2). Coupling of Boc-amino acid 6 with commercially available -threonine benzyl ester 7 using EDCI and HOBT in the presence of DPEA gave dipeptide 8. Oxidation of the secondary alcohols of 8 with the Dess-Martin reagent followed by cyclodehydration using iodine/triphenylphosphine in the presence of 4-dimethyl aminopyridine (DMAP) and TEA afforded oxazole 10. IR spectrum of oxazole 10 showed a stretching NH band at 3424 cm⁻¹ and C—O stretching bands at 1755, 1740, and 1710 cm⁻¹, consistent with the proposed structure and literature data on similar compounds [26]. The 1H NMR spectrum of oxazole 10 showed signals for the benzyl group at 7.45–7.28 ppm (m, 5H, Ar-H) and 5.34 (s, 2H, CH(CH₃)₂) in good yield through treatment of the salt as a hydrochloride salt.

2.2. Biological activities

2.2.1. Detection of in vitro cytotoxicity

A colorimetric MTT assay [33] was used to assess the cytotoxicity of 13, 14, and 15a-c on Vero-E6 cells. The results showed that their CC₅₀ ranged from 159.1 to 741.8 μM and their safety indices ranged from 2.50 to 39.1 (Table 1, Fig. 4a). Two of the best SARS-COV-2 inhibitors are 13 and 14 with IC₅₀ of 18.3 and 18.95 μM and SI of 20.8 and 39.1.

2.2.2. Anti-SARS-CoV-2 activity

The inhibitory effect of compounds 13, 14, and 15a-c on SARS-COV-2 (NRC-03-nhCoV) virus in Vero-E6 cells were evaluated as previously described [34–37]. Results from Table 1 showing that most of the compounds tested significantly inhibited the replication of the NRC-03-nhCoV virus in a dose-dependent profile. Triester macrocycle 13 and triamide macrocycle 14 demonstrated superior inhibitory activity compared to carboxamides 15a-c (Table 2, Fig. 4b). The strongest anti-SARS-COV-2 compounds are 13, 14 and 15a, which showed IC₅₀ of 18.3, 18.95 and 24.69 μM, respectively. The triester macrocycle 13 (R =

![Scheme 1](attachment:image_url)

**Scheme 1.** Synthesis of carboxylic acid 6. **Reagents and conditions:** (i) Boc₂O, NaHCO₃, NaCl, DCM/H₂O, reflux for 1.5 h, 92%; (ii) CH₃J, CH₂ONa, CH₃OH, stir at 50°C for 2 h, 79%; (iii) PLE, K₂HPO₄, KH₂PO₄, H₂O/CH₃CN, stir 5 days at rt, 91%; (iv) isopropyl alcohol, DCC, DMAP, stir at rt for 20 h, 77%; (v) LiOH, THF/H₂O, stir at rt for 2 h, 94%.
Scheme 2. Synthesis of oxazole building block **12**. Reagents and conditions: (i) HOBt, EDC, DIPEA, DMF, rt, overnight, 74%; (ii) Dess–Martin, DCM, rt, 4 h; (iii) PPh₃, I₂, TEA, DMAP, DCM, rt, 5 h, 84%; (iv) Pd/C (10%), H₂, EtOAc, rt, overnight, 87%; (v) 4 M HCl in dioxane, rt, 1.5 h, greater than 99%.

Scheme 3. Synthesis of macrocycles **13, 14** and **15a-c**. Reagents and conditions: (i) BOP, DIPEA, DMF, 24 h, rt, 60%; (ii) 5% NaOH, EtOH, 0 °C, 1 h, quantitative; (iii) Appropriate amine, BOP, DIPEA, DCM, overnight, rt, 70–75%.

**15a, R** = phenethylamine

**15b, R** = 4-(piperidin-1-yl)phenylethylamine

**15c, R** = 4-(N,N-dimethylamine)phenylethylamine
isopropyl) was the most effective synthesized derivatives with an IC \( \text{IC}_{50} \) value of 18.3 µM. Replacement of the isopropyl group in compound 13 by (H) in triacid 14 (R = H) decreases the activity of 14 (IC \( \text{IC}_{50} = 3.82 \mu\text{M} \)) which indicated the importance of the hydrophobic isopropyl group for activity. Large substituents at the R position such as phenethylamine (15a), 4-(piperidin-1-yl)phenethylamine (15b), and 4-(N,N-dimethylamino)phenethylamine (15c) groups decrease the activity of the compounds with IC \( \text{IC}_{50} \) of 7.35 µM, 15.34 µM, and 18.32 µM, respectively.

### 2.3. Molecular docking study

Given the promising activity of new macrocyclic compounds 13, 14, and 15a-c against COVID-19, we conducted a molecular docking study to investigate possible binding patterns and interactions of the compounds in the active site of COVID-19 main protease (SARS-CoV-2 M\(^{\text{pro}}\)).

The 3-dimensional crystal structure of SARS-CoV-2 M\(^{\text{pro}}\) (PDB ID: 6LU7) in complex with non-covalent inhibitor Molecule-5948770040 was downloaded from the protein data bank (https://www.rcsb.org/structure/6LU7) and the docking simulation process was accomplished using AutoDock Vina [41] as docking module embedded in AutoDockTools [42,43]. Ligands and protein files were prepared using Discovery Studio Visualizer [44], AutoDockTools, and docked to SARS-CoV-2 M\(^{\text{pro}}\) (PDB ID: 6LU7) with AutoDock Vina.

Validation of the docking was performed using the recently reported X-ray structure of SARS-CoV-2 M\(^{\text{pro}}\) in complex with non-covalent inhibitor Molecule-5948770040 (PDB ID: 7LTJ) [45]. Examination of the crystal structure indicated that Molecule-5948770040 binding position is probably not significantly influenced by bridging water molecules, contrary to some other non-covalent inhibitors. The shapes of the binding sites in 6LU7 and 7LTJ are highly identical and structure 7LTJ was deemed appropriate for performing the docking validation as Molecule-5948770040 is non-covalent inhibitor. Remarkably in this case, the highest scoring pose (−9.4 kcal/mol) for the re-docking of Molecule-5948770040 was found to have an almost identical binding position and conformation to that of the ligand in the crystal structure (RMSD of 0.1325 Å) [Fig. 5]. This validated the use of AutoDock Vina in the present docking study assuming that there are no major water-mediated interactions between the enzyme and the macrocyclic compounds.

Rebek triacid platform as well as ester and amide derivatives are known to adopt a quasiplanar structure stabilized by six bifurcated hydrogen bonds provided by the alternating oxazole (hydrogen-bond acceptor) and trans amide (hydrogen-bond donor) groups of the macrocycle [46,47]. The structures of compounds 13, 14, and 15a-c were prepared in Discovery Studio Visualizer using the MMFF94 force field [48] and submitted to docking via ADT on SARS-CoV-2 M\(^{\text{pro}}\) (PDB ID: 6LU7) with the ligand N3 and water molecules being removed.

Docking was initially performed using triester 13, which was found to dock to cavities of SARS-CoV-2 M\(^{\text{pro}}\), in particular the enzyme active site, site 2 and site 3 [Fig. 6]. However, the docking scores for the poses docked in the active site were significantly better. This also proved true for triacid and triamides 15a-c. We therefore focused on the binding mode of these compounds in the enzyme active site.

Fig. 7A shows a close-up view of the bound conformation of ligand N3 in PDB 6LU7 in comparison to the docked structure of triester 13 in the same enzyme active site (Fig. 7B). The large surface area of compound 13 complements well the relatively flat surface area of this part of the active site defined by Phe-140, His-163, Met-165, Glu-166, and Pro-168, with one of the hydrophobic isopropyl groups of the compound protruding into the recognition site of the benzyl group of N3. The methyl substituents of the oxazole rings and two methyl groups of the macrocyclic scaffold appear to complement small pockets (Fig. 7C and D). Discovery studio visualizer suggests the presence of a significant anion-s interaction between glutamate-166 and one of the oxazole rings of the ligand (Fig. 7E). The docking score for this pose was −7.5 kcal/
mol. Glu-189 and Asp-144 side chains also appear to lock the molecule in place. In fact, re-docking of the molecule with the enzyme where these side chains were rotated to offer additional hydrogen-bonding interactions with the ligand yielded a higher docking score of 8.8 kcal/mol (Fig. 7F). Additional hydrophobic interactions are also seen in this case with Pro-168.

Following the docking of triester 13, which has the best anti-COVID activity among the macrocycles tested, we studied the possible interactions that the enzyme could make with the other bioactive compounds triacid 14 and amide 15a (Fig. 8). AutoDock Vina docking results suggest that the triacid 14 and triester 13 can bind to the active site in an almost identical way. We can visualize the same shape complementarity of the platform with the binding site including almost identical hydrophobic interactions, the presence of the uncommon anion-π interaction, and the apparition of a weak hydrogen bond between one of the carboxylic acid groups and Asn-142. However, there are no protruding groups in this case to fill the N3 benzyl group binding site. Nevertheless, the binding energy obtained by AutoDock Vina for the triacid 14 (-7.9 kcal/mol) was found to be comparable to that obtained for the triester 13 (-7.5 kcal/mol).

Triamide 15a was also found to adopt a similar position as triester 13 and triacid 14 in the binding site, with essentially similar interactions with the platform. Additional interactions can also be seen, including an excellent size and shape complementarity of the V3 benzyl group binding site with one of the phenethyl groups of 15a, interacting with His-41, Leu-27 and Cys-145. The other phenethyl groups, however, cannot adopt low-energy extended conformations and this would cause a significant decrease in binding affinity. One of these groups would also make extensive contact with the bulk water affecting the overall binding. Despite this, AutoDock Vina estimated a binding energy of -8.3 kcal/mol. The CC<sub>50</sub> (50% cytotoxic concentration) of the tested macrocycles in Vero-E6 cells (Fig. 4a) and IC<sub>50</sub> (50% inhibitory concentration) against NRC-03-nCoV virus in Vero-E6 cells (4b). The CC<sub>50</sub> and IC<sub>50</sub> were plotted for each tested compound using Graph Pad Prism and were calculated from the non-linear regression curve-fit analysis, relative to the virus and cell controls.

Fig. 4. CC<sub>50</sub> (50% cytotoxic concentration) of the tested macrocycles in Vero-E6 cells (Fig. 4a) and IC<sub>50</sub> (50% inhibitory concentration) against NRC-03-nCoV virus in Vero-E6 cells (4b). The CC<sub>50</sub> and IC<sub>50</sub> were plotted for each tested compound using Graph Pad Prism and were calculated from the non-linear regression curve-fit analysis, relative to the virus and cell controls.
Table 2: Mechanisms of action of compounds 13, 14, and 15a.

| Compound | Conc. (µM) | Mode of action | IC₅₀ (µM) |
|----------|------------|----------------|----------|
|          |            | Viral adsorption | Viral replication | Virucidal |
| 13       | 20         | 52%             | 53%         | 57%       |
|          | 10         | 12%             | 23%         | 18%       |
|          | 5          | 0%              | 6%          | 12%       |
|          | 2.5        | 0%              | 0%          | 13%       |
| 14       | 20         | 66%             | 38%         | 60%       |
|          | 10         | 24%             | 36%         | 28%       |
|          | 5          | 16%             | 30%         | 12%       |
|          | 2.5        | 0%              | 0%          | 11%       |
| 15a      | 20         | 11%             | 51%         | 89%       |
|          | 10         | 9%              | 19%         | 58%       |
|          | 5          | 0%              | 5%          | 0%        |
|          | 2.5        | 0%              | 0%          | 0%        |

* The mechanism of action of the three compounds were done at concentrations higher than the half-maximal inhibitory effect (IC₅₀) to better resolve the mechanism of action.

Collectively, the docking study, along with in vitro SARS-CoV-2 M⁰ results, seem to indicate that the active site of the protease can accommodate large molecules. The docking study suggests that derivatives of triester 13, which feature elements of triacid 14 and triamide 15a, as well as modifications of the tris(oxazole) platform using appropriate substituents could lead to highly active SARS-CoV-2 M⁰ inhibitors.

3. Conclusion

A small set of new oxazole-based macrocycles 13, 14, and 15a-c synthesized, and tested for their anti-SARS-COV-2 activity. Compounds 13, 14 and 15a showed promising inhibitory properties for the SARS-CoV-2 (NRC-03-nhCoV) virus in Vero-E6 cells, and the SARS-CoV-2 main protease assay revealed significant inhibitory effects of these compounds. This mechanism of action is further supported by docking experiments which have shown that most of the tested compounds fit well within the SARS CoV-2 M⁰ active pocket. The results of the docking study are consistent with the in vitro SARS CoV-2 M⁰ inhibitory activities of the compounds. Taken together, these oxazole-based macrocyclic compounds could constitute promising leads for further optimization and development against SARS-CoV main proteases, and open new avenues to help defeat future infections by coronavirus variants.

4. Experimental

4.1. Chemistry

General details: See Appendix A

4.1.1. Dimethyl 2-(tert-butoxycarbonylamino)malonate (2)

To a stirred suspension of dimethyl amino malonate hydrochloride (11.9 g, 64.26 mmol, 1 eq) in CHCl₃ (50 mL), NaHCO₃ (6.4 g, 1.2 eq) dissolved in H₂O (10 mL), NaCl (4.54 g, 1.2 eq), and Boc₂O (17 g, 1.2 eq) were added to reaction mixture with refluxing for 1.5 h. After cooling, the organic layer was separated, dried over anhydrous Na₂SO₄, and evaporated under reduced pressure to give 18.5 g (92%) of 2 as yellow oil after purification by flash chromatography using EtOAc/ hexane (1:2) as an eluent. 

1H NMR (250 MHz, CDCl₃) δ 5.54 (s br, 1H, NH), 4.95 (d, J = 8.0 Hz, 1H, NHCH₂), 3.75 (s, 6H, 2 × OCH₃), 1.38 (s, 9H, C(CH₃)₃). 13C NMR (62.5 MHz, CDCl₃) δ 167.0 (C=O), 154.74 (NHC=O), 85.1, 57.2, 53.3, 28.2.

4.1.2. Dimethyl 2-(tert-butoxycarbonylamino)-2-methylmalonate (3)

A mixture of 2 (18 g, 72.8 mmol, 1 eq) and CH₃ONa (15.64 mL) in CH₂OH (20 mL) were charged to double necked flask equipped with condenser. Methyl iodide (5.45 mL, 1.2 eq) was added dropwise to the reaction mixture over period of 30 mins with stirring at 50 °C and the stirring was continued for another 1.5 h at the same temperature. After removal of solvent under reduced pressure, saturated solution NH₄Cl (10 mL) were added and reaction mixture was extracted with EtOAc, washed with brine, dried over MgSO₄ and evaporated under reduced pressure to give 14 g (79 %) of 3 as a colorless oil. ν max (neat, film)/ cm⁻¹ 3434 (NH), 2981, 2850, 1750 (C=O), 1488, 1369, 1290, 1171, 1104, 1062. 1H NMR (250 MHz, CDCl₃) δ 5.95 (s br, 1H, NH), 3.76 (s, 6H, 2 × OCH₃), 1.71 (s, 3H, CH₃), 1.40 (s, 9H, C(CH₃)₃). 13C NMR (62.5 MHz, CDCl₃) δ 170.4, 169.4, 153.6, 80.1, 62.9, 53.5, 28.2, 21.7. HRESI-MS m/z calcd for [M + H]⁺ C₁₃H₂₃NO₆: 262.1285, found: 262.1287.

4.1.3. (R)-2-(tert-butoxycarbonylamino)-3-methoxy-2-methyl-3-oxopropanoic acid (4)

In three-liter beaker with magnetic stirrer, K₂HPO₄ (31.23 g, 3.5 eq) and KH₂PO₄ (17.42 g, 2.5 eq) were dissolved in water (1800 mL). Then PLE (0.495 g, 5000 units Sigma) was added with vigorous stirring for 15 min at rt. A solution of 3 (13.3 g, 51.67 mmol, 1 eq) dissolved in CH₂CN...
(450 mL) was added to reaction mixture with the vigorous stirring for 5 days. pH of the reaction mixture was maintained during reaction time between 7.5 and 8.5. After adjusted of pH = 3 by 1 N HCl, EtOAc and NaCl were successively added with stirring at rt for 5 mins. The separated organic layer was dried over anhydrous MgSO4 and evaporated under reduced pressure to give 11.2 g (91%) of 4 as a white solid, mp 112–114°C. rmax (KBr disc)/cm⁻¹ 3350 (OH and NH), 2950, 1732 (C=O), 1694 (C=O), 1651 (C=O), 1511, 1509, 986, 902, 774, 640.¹H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H, NH), 3.78 (s, 3H, OCH3), 1.78 (s, 3H, CH3), 1.41 (s, 9H, C(CH3)3).¹³C NMR (101 MHz, CDCl3) δ 171.6 (COOH), 169.1, 156.2, 83.3, 52.8, 28.1, 21.9. HRESI-MS calcd for [M + H]+ C13H22N2O6: 246.0983, found: 246.0976.

4.1.6. Benzyl 2-((S)-2-(tert-butoxycarbonylamino)-3-isopropoxy-2-methyl-3-oxo-propan amido)-3-hydroxybutanoate (8)

To a stirred solution of 6 (5 g, 18.16 mmol, 1 eq) in DMF (70 mL), HOBT (1.93 g, 1 eq), EDC (1.93 g, 1 eq), i-threonine benzyl ester 7 (6.44 g, 1.2 eq) were added and reaction mixture was cooled to 0°C before dropwise addition of DIPEA (1.05 mL, 1.2 eq) then the reaction mixture was stirred overnight at rt. The reaction mixture was diluted with EtOAc and successively washed twice with H2O. The organic layer was washed with 5% aqueous HCl, saturated NaHCO3, and finally with brine. The organic phase was dried over MgSO4 and the solvent was removed under reduced pressure to yield 6.10 g (74%) of 8 as a colourless oil which solidify to a white solid after chromatographed on silica gel using EtOAc/hexane (1:1) as an eluent. rmax (neat, film)/cm⁻¹ 3434 (NH), 2981, 2850, 1760 (C=O), 1491, 1450, 1376, 1282, 1102, 1061, 753, 699.¹H NMR (400 MHz, CDCl3) δ 4.78-7.00 (m, 6H, Ar-H, NHC=O): 6.02 (s, 1H, NHCOO), 5.16 (d, J = 5.0 Hz, 2H, PhCH2), 5.05 (h, J = 6.3 Hz, 1H, CH(CH3)2), 4.57 (dd, J = 8.9, 2.7 Hz, 1H, NHCH), 4.34-4.30 (m, 1H, CHOH), 2.69 (s, 1H, OH), 1.71 (s, 3H, CH3), 1.41 (s, 9H, C(CH3)3), 1.21 (d, J = 6.3 Hz, 6H, CH(CH3)2), 1.14 (d, J = 4.6 Hz, 3H, CH2CH3).¹³C NMR (101 MHz, CDCl3) δ 170.5, 170.2, 168.6, 154.3, 135.2, 128.6, 128.4, 128.2, 70.5, 67.9, 67.3, 62.9, 57.9, 28.2, 21.5, 21.4, 19.9. HRESI-MS m/z calcd for [M + H]+ C23H32N2O6: 467.2388, found: 467.2394.

4.1.7. Benzyl 2-((S)-2-(tert-butoxycarbonylamino)-3-isopropoxy-2-methyl-3-oxo-propanamido)-3-chlorobutanoate (9)

To a solution of 8 (3.6 g, 7.74 mmol, 1 eq) in DCM (70 mL), Dess-Martin periodinane (4.26 g, 1.3 eq) was added with stirring at 0°C for 30 mins then the temperature was warmed to rt for 4 h. Saturated solution of Na2S2O3 (20 mL) and saturated solution of NaHCO3 (20 mL) were added to reaction mixture with stirring at rt for 15 mins. The organic layer was separated, dried over Na2SO4 and evaporated under reduced pressure to yield a crude product which was used for next step without further purification.

(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
4.1.8. (S)-benzyl 2-(2-(tert-butoxycarbonylamino)-1-isopropoxy-1-oxopropan-2-yl)-5-methyloxazole-4-carboxylate (10)

To a solution of 9 (2.48 g, 5.34 mmol, 1 eq) in DCM (100 mL), triethylamine (TEA, 2.96 mL, 4 eq), and DMAP (0.064 g, 0.1 eq) were added with stirring for 1 h at rt. Triphenylphosphine (PPh$_3$, 1.68 g, 1.2 eq) was added to reaction mixture followed by portion wise addition of iodine (1.63 g, 1.2 eq) at 0 °C. The cooling bath was removed after 30 mins and stirring was continued at rt for 5 h. The solvent was removed under reduced pressure. The residue was diluted with Et$_2$O to enhance the precipitation of triphenylphosphine oxide (OPPh$_3$) which was filtered out. Pure oxazole was obtained after flash chromatography of crude product using a mixture of ethyl acetate, hexanes (1:4) as an eluent to give 2 g (84%) of 10 as a colourless oil. $\nu_{\text{max}}$ (neat, film)/cm$^{-1}$ 3424 (NH), 2980, 1755 (C–O), 1740 (C–O), 1719 (C–O), 1618, 1491,

Fig. 7. (A) and (B): Electrostatic surface representation of COVID-19 main protease showing the position of ligand N3 and docked triester 13, respectively, within the enzyme active site. (C) and (D): Solvent access surface (yellow, probe radius of 1.4 Å) representation of COVID-19 main protease binding site, side view and top view (respectively) for the best binding pose of triester 13. (E) 2D interaction diagram for the best docking pose of triester 13. Docking score of −7.5 kcal/mol (F) 2D interaction diagram for the best docking pose of triester 13 after rotation of Gln189 and Asn142 side chains and re-docking showing additional interactions between the ligand and protein (docking score of −7.8 kcal/mol). The ligands were rendered using the stick representation. Non-polar hydrogen atoms were omitted for clarity. $\text{CH}-\pi$ and hydrophobic interactions are shown in pink, conventional hydrogen bonds are shown in green, anion-$\pi$ interactions are shown in orange. The strength of the interactions is approximately proportional to the size of the blue circles. Filled blurry purple circles indicate groups in contact with the solvent. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
1458, 1368, 1280, 1170, 753, 699. \( ^1H \) NMR (400 MHz, CDCl₃) δ 7.45–7.28 (m, 5H, Ar-H), 6.14 (s, 1H, NH), 5.34 (s, 2H, PhCH₂), 5.02 (h, \( J = 6.3 \) Hz, 1H, CH(CH₃)₂), 2.56 (s, 3H, oxazole-CH₃), 1.94 (s, 3H, CCH₃), 1.38 (s, 9H, C(CH₃)₃), 1.16 (dd, \( J = 17.1, 6.2 \) Hz, 6H, CH(CH₃)₂).

\( ^{13}C \) NMR (101 MHz, CDCl₃) δ 168.7, 161.9, 160.1, 157.0, 153.8, 135.7, 128.5, 128.4, 128.3, 127.6, 80.2, 70.6, 66.5, 58.9, 28.2, 21.4, 21.3, 12.2.

HRESI-MS \( m/z \) calcd for [M + H]⁺ C₂₃H₃₁N₂O₇: 447.2126, found: 447.2124.

4.1.9. (S)-2-(2-(tert-butoxycarbonylamino)-1-isopropoxy-1-oxopropan-2-yl)-5-methyl oxazole-4-carboxylic acid (11)

To a vigorous stirred solution of oxazole 10 (1.2 g, 2.88 mmol) in EtOAc (15 mL) in two-necked flask purge with N₂, Pd/C (10%, 0.26 g) was added. The reaction mixture was stirred overnight under balloon of hydrogen at rt. Pd/C was filtered through double filter paper and EtOAc was removed under reduced pressure to give 0.83 g (87%) of pure corresponding acid 11 as a colourless oil. \( \nu \)max (neat, film)/cm⁻¹ 3419 (br, OH, NH), 2984, 1750 (C=O), 1655 (C=O), 1617 (C=O), 1491, 1369, 1285, 1110, 752. \( ^1H \) NMR (400 MHz, CDCl₃) δ 6.52 (s, 1H, NH), 5.03 (h, \( J = 6.3 \) Hz, 1H, CH(CH₃)₂), 2.60 (s, 3H, oxazole-CH₃), 1.94 (s, 3H, CCH₃), 1.36 (s, 9H, C(CH₃)₃), 1.16 (dd, \( J = 17.1, 6.2 \) Hz, 6H, CH(CH₃)₂).

\( ^{13}C \) NMR (101 MHz, CDCl₃) δ 168.7, 165.5, 160.2, 157.8, 154.0, 127.4, 70.8, 60.4, 58.8, 28.2, 21.4, 21.3 for (CH₃)₂, 21.0, 12.2.

HRESI-MS \( m/z \) calcd for [M + H]⁺ C₁₆H₂₅N₂O₇: 357.1656, found: 357.1653.

4.1.10. (S)-2-(4-carboxy-5-methyloxazol-2-yl)-1-isopropoxy-1-oxopropan-2-aminium chloride (12)

To a vigorous stirred solution of oxazole 10 (1.2 g, 2.88 mmol) in EtOAc (15 mL) in two-necked flask purge with N₂, Pd/C (10%, 0.26 g) was added. The reaction mixture was stirred overnight under balloon of hydrogen at rt. Pd/C was filtered through double filter paper and EtOAc was removed under reduced pressure to give 0.83 g (87%) of pure corresponding acid 11 as a colourless oil. \( \nu \)max (neat, film)/cm⁻¹ 3419 (br, OH, NH), 2984, 1750 (C=O), 1655 (C=O), 1617 (C=O), 1491, 1369, 1285, 1110, 752. \( ^1H \) NMR (400 MHz, CDCl₃) δ 6.52 (s, 1H, NH), 5.03 (h, \( J = 6.3 \) Hz, 1H, CH(CH₃)₂), 2.60 (s, 3H, oxazole-CH₃), 1.94 (s, 3H, CCH₃), 1.36 (s, 9H, C(CH₃)₃), 1.16 (dd, \( J = 17.1, 6.2 \) Hz, 6H, CH(CH₃)₂).

\( ^{13}C \) NMR (101 MHz, CDCl₃) δ 168.7, 165.5, 160.2, 157.8, 154.0, 127.4, 70.8, 60.4, 58.8, 28.2, 21.4, 21.3 for (CH₃)₂, 21.0, 12.2.

HRESI-MS \( m/z \) calcd for [M – Cl]⁻ C₁₆H₁₇N₂O₅: 257.1137, found: 257.1132.
4.1.11. Synthesis of triester macrocycle (13)
To a stirred solution of 12 (0.6 g, 2.054 mmol, 1 eq) in DMF (80 mL), BOP (2.73 g, 2 eq) and DIEPA (2.5 mL, 7 eq) was added at 0 °C with stirring for 1 h, then the temperature was warmed to rt for 24 h. The reaction mixture was diluted with EtOAc and successively washed with H₂O to separate EtOAc layer. The EtOAc layer was washed with 5% HCl, saturated NaHCO₃, and brine. The organic phase was dried over MgSO₄, and the solvent was removed under reduced pressure to yield 0.29 g (60%) of pure triester macrocycle 13 as a white solid after chromatography on silica gel using EtOAc/ hexane (2:3) as an eluent.

4.1.12. Synthesis of triacid platform (14)
A mixture of the triacid platform 13 (0.2 g, 0.32 mmol) and 5% NaOH (8 mL) in ethanol (20 mL) was stirred at 0 °C for 1 h. The residue after removal of ethanol under reduced pressure was then taken into water, precipitated at pH = 1 using 5% HCl, extracted twice with EtOAc, dried over MgSO₄, and evaporated under vacuo to give 0.18 g (95%) of pure triacid platform 14 as a white solid, mp 268–270 °C. νmax (KBr disc)/cm⁻¹ 3378 (br, OH and NH), 2960, 1683 (C=O), 1515, 1520, 1441, 1304, 1239, 1188, 1133, 915, 780, 738, 656. ¹H NMR (400 MHz, CDCl₃): δ 8.06 (s, 3H, 3 × NHCHₓ), 2.66 (s, 9H, 3 × oxazole-CHₓ), 2.03 (s, 9H, 3 × CHₓCH₃). ¹³C NMR (62.5 MHz, CDCl₃): δ 170.4, 161.9, 160.1, 157.3, 129.6, 60.4, 22.7, 11.7. HRESI-MS m/z calcd for [M + NH₄]+ C₈₂H₃₃N₁₂O₁₂: 606.1790, found: 606.1786.

4.1.13. General procedure for synthesis of macroyclic carboxamides (15a-c)
A mixture of the triacid platform 14 (0.05 g, 0.085 mmol, 1 eq), BOP (0.14 g, 3.6 eq.), and DIEPA (0.1 mL, 6 eq.) in DCM (10 mL) was stirred for 10 mins at rt before addition of an appropriate amine (3.4 eq) e.g., phenethylamine, 4-(piperidin-1-yl)phenethylamine, 4-(N,N-dimethylamino)phenethylamine and the resulting reaction mixture was stirred overnight at rt. After removing of the solvent in vacuo, the residue was extracted with EtOAc, washed with 5% HCl, saturated NaHCO₃ solution, brine, dried over MgSO₄, and evaporated under reduced pressure to give a crude product which was purified by flash chromatography on silica gel using EtOAc/ hexane (1:2) as an eluent to afford the corresponding carboxamides.

4.1.13.1. Macrocycle carboxamide (15a). mp 168–170 °C as a white solid. νmax (KBr disc)/cm⁻¹ 3340 (NH), 2960, 1683 (C=O), 1634 (C=O), 1506, 1453, 1187, 841, 749, 701. ¹H NMR (400 MHz, DMSO-d₆): δ 8.74 (s, 3H, 3 × NHC = O), 8.27 (t, J = 5.7 Hz, 3H, 3 × NHCHₓ), 7.23–7.06 (m, 15H, 3 × Ar-H), 3.27 (q, J = 7.2 Hz, 6H, 3 × NHC(CHₓ)₂), 2.68 (t, J = 7.1 Hz, 6H, 3 × NHCH(CHₓ)₂), 2.57 (s, 9H, 3 × oxazole-CHₓ), 1.95 (s, 9H, 3 × CHₓCH₃). ¹³C NMR (101 MHz, DMSO-d₆): δ 166.6, 160.4, 159.5, 155.0, 139.8, 129.0, 128.6, 128.3, 126.4, 59.7, 41.7, 35.1, 21.8, 11.9. HRESI-MS m/z calcd for [M + H]+ C₈₅H₅₁N₁₁O₁₃: 898.3883, found: 898.3884.

4.1.13.2. Macrocycle carboxamide (15b). mp 180–182 °C as a white solid. νmax (KBr disc)/cm⁻¹ 311.70 (s, 3H, 3 × NH = O), 8.84 (t, J = 5.5 Hz, 3H, 3 × NHCHₓ), 7.10 (d, J = 8.0 Hz, 6H, Ar-H), 6.84 (d, J = 8.0 Hz, 6H, Ar-H), 3.51 (q, J = 7.2 Hz, 6H, 3 × NHCH(CHₓ)₂), 3.30 (s, 9H, 3 × oxazole-CHₓ), 3.05 (t, J = 5.2 Hz, 12H, piperidin-H), 2.75 (t, J = 7.2 Hz, 6H, 3 × NHCH₂CHₓ), 1.97 (s, 9H, 3 × CCHₓ) 1.62–1.47 (m, 18H, piperidin-H). ¹³C NMR (101 MHz, DMSO-d₆): δ 167.5, 161.4, 159.0, 154.8, 148.2, 129.5, 129.2, 127.9, 111.9, 55.8, 40.1, 36.5, 25.6, 25.4, 24.2, 11.5. HRESI-MS m/z calcd for [M + H]+ C₉₀H₇₆N₁₂O₁₄: 1147.6087, found: 1147.6089.

4.1.13.3. Macrocycle carboxamide (15c). mp 178–180 °C as a white solid. νmax (KBr disc)/cm⁻¹ 3876 (s, 3H, 3 × NH = O), 8.22 (t, J = 5.8 Hz, 3H, 3 × NHCHₓ), 6.91 (d, J = 8.5 Hz, 6H, Ar-H), 6.56 (d, J = 8.5 Hz, 6H, Ar-H), 3.20 (q, J = 6.6 Hz, 6H, 3 × NHCH₂CHₓ), 2.78 (s, 18H, 3 × NH(CHₓ)₂), 2.66 – 2.50 (m, 15H, 3 × NHCH₂CHₓ, 3 × oxazole-CHₓ), 1.94 (s, 9H, 3 × CHₓ). ¹³C NMR (101 MHz, DMSO-d₆): δ 166.5, 160.4, 159.6, 155.0, 149.3, 129.5, 129.4, 128.3, 113.0, 59.7, 42.1, 40.8, 34.1, 21.8, 11.8. HRESI-MS m/z calcd for [M + H]+ C₉₃H₇₄N₁₂O₁₄: 1027.5148, found: 1027.5143.

4.2. Biological Studies

In vitro bioassay of cytotoxicity [33], antiviral activity [34–37], mode of action(s) [36], and inhibitory bioassay against SARS-CoV-2 MPro [40] were performed according to previously reported procedures. See Appendix A.

4.3. Molecular Docking

4.3.1. Preparation of receptor molecular coordinate files
The crystallography coordinates of the complexes were downloaded as pdb files. The files were loaded in AutoDockTools, the ligand(s) and water molecules were removed, hydrogens and charges were added, and the structures were saved as pdbqt files.

4.3.2. Preparation of the ligands’ molecular coordinate files
The ligands were drawn in Discovery Studio Visualizer, energy minimized by molecular mechanics (MMFF force field) and saved as mol2 files. These ligand files were loaded in AutoDockTools, hydrogen atoms and charges were added, all the relevant bonds were made rotatable, and the files were saved as pdbqt files.

4.3.3. Docking
A Grid Box was manually defined in AutoDockTools to perform docking in the enzyme active site. A config.txt file was prepared indicating the receptor and ligand file names, the Grid Box coordinates and size, the energy range (4 kcal/mol) and exhaustiveness of the docking (set to 8). AutoDock Vina docking was started from the AutoDockTools built-in GUI interface. Each docking was run five times. The docking poses (in pdbqt format) and scores were visualized in AutoDockTools, and were exported for further analyses in Discovery Studio Visualizer.

Funding
This research was funded by the Deanship of Scientific Research at Princess Nourah bint Abdulrahman University through the Fast-track Research Funding Program.

Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bioorg.2021.105363.

References

[1] M.Z. Tay, C.M. Poh, L. Renta, P.A. MacArry, L.F.P. Ng, The trinity of COVID-19: community, infection, and intervention, Nat. Rev. Immunol. 20 (2020) 363–374.

[2] E. Estrada, Topological analysis of SARS-CoV-2 main protease, Chaos 30 (2020), 061102.

[3] L. Zhang, D. Lin, X. Sun, U. Carth, C. Droston, L. Sauerthering, S. Becker, K. Rux, R. Hilgenfeld, Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketohydantin inhibitors, Science 368 (2020) 409–412.

[4] W. Dai, B. Zhang, X.-M. Jiang, H. Su, J. Li, Y. Zhao, X. Xie, Z. Jin, J. Peng, F. Liu, C. Li, Y. Li, F. Bai, H. Wang, X.-I. Cheng, X. Gen, S. Hu, X. Yang, J. Wang, X. Liu, G. Xiao, H. Jiang, Z. Rao, L.-K. Zhang, Y. Xu, H. Yang, H. Liu, Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease, Science 367 (6497) (2020) 1331–1335.

[5] WHO Coronavirus Disease (COVID-19) Dashboard, https://covid19.who.int/.

[54] Y. Touahji, Kouhei Matsui, Haruaki Nobori, Haruka Maeda, Akihiko Sato, Takeshi Kurouzu, Yusako Orba, Hirofumi Sawa, Kazunari Hattori, Kenichi Hishigoshi, Yoshito Numata, Yutaka Yoshida, Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity, Bioorg. Med. Chem. Lett. 27 (15) (2017) 3586–3590.

[75] Xin Ma, Xu-Hua Nong, Zhe Ren, Jie Wang, Luang L, Shu-Hua Qi, Antiviral peptides from marine gorgonian-derived fungus Arpilgillus sp. SCI. 41501, Tetrahedron Lett. 58 (12) (2017) 1151–1155.

[101] C.B. Mcclain, N. Valeret, SARS-CoV-2: The many pros of targeting Plero, Signal Transduct. Target. Ther. 5 (2020) 223.

[114] G. Derosa, P. Maffioli, A. D’Enia, P.A. MacAry, L.F.P. Ng, The trinity of COVID-19: community, infection, and intervention, Nat. Rev. Immunol. 20 (2020) 363–374.

[123] P. Amorin, M.R. Ghadiri, G. Haberhauer, S.C. Ceide, L. Trembleau, L. Somogyi, L. Krock, J. Rebek, Galmic, a generation pseudopeptide platform, Tetrahedron Lett. 41 (26) (2000) 5013–5016.

[132] J. S. Nowick, Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: a tutorial for students and scientists, ChemRxiv. 2020;10.26434/chemrxiv.12791954.v1.

[141] W.S. Horne, C.M. Wiethoff, C. Cui, K.M. Wilcoxen, M. Amorin, M.R. Ghadiri, G.R. Nemerow, Antiviral cyclic di L-α-lactides: targeting a general biochemical pathway in virus infections, Bioorg. Med. Chem. 13 (2005) 5145–5153.

[150] Guan-Wen Lu, Wei-Min Li, Yu-Quan Wei, Yong-Tang Zheng, Jian Lei, Ming Liu, Pei Chen, Yang Liu, Gui-Feng Lin, Ying-Yuan Gao, developing SARS-CoV-2 inhibitors with potential antiviral activity in a transgenic mouse model, Science 371 (6536) (2021) 1374–1378.

[159] L. Fu, F. Fei, F. Feng, Y. Wu, Q. Wang, Z. Zhao, H. Huang, P. Niu, H. Song, Y. Shi, X. Li, W. Tan, J. Qi, G.F. Gao, Both Beceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease, Nat. Commun. 11 (2020) 4417.

[169] A. Abdulla, L.J. McGaw, Natural cyclic peptides as an attractive modality for drug design, Sci. Adv. 6 (42) (2020) eabd4596, https://doi.org/10.1126/sciadv.2005591.

[178] T. Huang, M. Bekes, M. Drag, S.K. Olsen, Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design, Sci. Adv. 6 (50) (2020) eabe0751, https://doi.org/10.1126/sciadv.2004033.

[187] M. A. Abdalla, L. J. McGaw, Natural cyclic peptides as an attractive modality for drug design, Sci. Adv. 6 (50) (2020) eabe0751, https://doi.org/10.1126/sciadv.2004033.

[196] J. Saffran, L. Aubry, M. Hamza, A. Caillou, M. A. Becker, C. Fischer, R. Arutyunova, C. Lamer, J. Shields, T. Vuong, L.Quan Wei, Ying-Tang Zheng, Jian Lei, Shengyong Yang, SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model, Science 371 (6536) (2021) 1374–1378.

[205] L. Fu, F. Fei, F. Feng, Y. Wu, Q. Wang, Z. Zhao, H. Huang, P. Niu, H. Song, Y. Shi, X. Li, W. Tan, J. Qi, G.F. Gao, Both Beceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease, Nat. Commun. 11 (2020) 4417.
[42] M.F. Sanner, Python: A programming language for software integration and development, J. Mol. Graphics Mod. 17 (1999) 57-61.
[43] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A. J. Olson, Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility, J. Comput. Chem. 16 (2009) 2785-2791.
[44] BIOVIA, Dassault Systèmes, Discovery Studio Visualizer v16.1.0.15350, San Diego: Dassault Systèmes, 2015.
[45] A. Clyde, S. Galanie, D. W. Kneller, H. Ma, Y. Babuji, B. Blaiszik, A. Brace, T. Brettin, K. Chard, R. Chard, L. Coates, I. Foster, D. Hauner, V. Kertesz, N. Kumar, H. Lee, Z. Li, A. Merzky, J. G. Schmidt, L. Tan, M. Titov, A. Trifan, M. Turilli, H. Van Dam, S. C. Chenubbhoda, S. Jha, A. Kovalevsky, A. Ramanathan, M. S. Head, R. Stevens; High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent Inhibitor. bioRxiv 2021.03.27.437323; doi: https://doi.org/10.1101/2021.03.27.437323.
[46] D. Mink, S. Mecozzi, J. Rebek Jr., Natural products analogues as scaffolds for supramolecular and combinatorial chemistry, Tetrahedron Lett. 39 (1998) 5709-5712.
[47] Gebhard Haberhauer, Eugen Drosdow, Thomas Oeser, Frank Rominger, Structural investigation of westiellamide analogues, Tetrahedron 64 (8) (2008) 1853–1859.
[48] Thomas A. Halgren, Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94, J. Comput. Chem. 17 (5-6) (1996) 490-519.
[49] Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, B. Zhang, X. Li, L. Zhang, C. Peng, Y. Duans, J. Yu, Y. Wang, X. Yang, F. Liu, R. Jiang, X. Yang, T. You, X. Liu, X. Yang, F. Bai, H. Liu, X. Liu, L.W. Guddat, W. Xu, G. Xiao, C. Qin, Z. Shi, H. Jiang, Z. Rao, H. Yang, Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors, Nature 582 (2020) 289–293.